3 citations
,
January 2023 in “Clinical cancer investigation journal” This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.
December 2023 in “International Journal of Pharmaceutics” This study developed innovative silica/natural polysaccharide hybrid nanoparticles encapsulating plant-derived 5-alpha-reductase inhibitors, reporting effective controlled release at hair follicle pH and lower cytotoxicity, suggesting a promising delivery system for antiandrogenic treatments.
November 2023 in “ACS Omega” This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.
27 citations
,
January 2017 in “Neuropsychopharmacology” This study found that acute sleep deprivation enhanced 5α-reductase expression and activity in the rat prefrontal cortex, and finasteride treatment reduced associated psychosis- and mania-like behaviors.
1 citations
,
October 2013 in “Our Dermatology Online” This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.